Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism

被引:128
作者
Goldwasser, Jonathan [2 ,3 ,4 ]
Cohen, Pazit Y. [1 ]
Lin, Wenyu [4 ]
Kitsberg, Danny [1 ]
Balaguer, Patrick [5 ]
Polyak, Stephen J. [6 ]
Chung, Raymond T. [4 ]
Yarmush, Martin L. [2 ,4 ]
Nahmias, Yaakov [1 ,2 ,4 ]
机构
[1] Hebrew Univ Jerusalem, Selim & Rachel Benin Sch Engn, Jerusalem, Israel
[2] Shriners Burns Hosp, Ctr Engn Med, Boston, MA USA
[3] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA
[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[5] Univ Montpellier I, INSERM, Montpellier, France
[6] Univ Washington, Seattle, WA 98195 USA
基金
欧洲研究理事会;
关键词
HCV; Naringenin; Lipid metabolism; PPAR alpha; TRIGLYCERIDE TRANSFER PROTEIN; ACTIVATED RECEPTOR-ALPHA; EXPRESSION; SECRETION; INTERFERON; FLAVONOIDS; HCV;
D O I
10.1016/j.jhep.2011.02.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background & Aims: Hepatitis C virus (HCV) infection affects 3% of the world population and is the leading cause of chronic liver disease worldwide. Current standard of care is effective in only 50% of the patients, poorly tolerated, and associated with significant side effects and viral resistance. Recently, our group and others demonstrated that the HCV lifecycle is critically dependent on host lipid metabolism and that its production is metabolically modulated. Methods: The JFH1/Huh7.5.1 full lifecycle model of HCV was used to study the antiviral effects of naringenin on viral replication, assembly, and production. Activation of PPAR alpha was elucidated using GAL4-PPAR alpha fusion reporters, PPRE reporters, qRT-PCR, and metabolic studies. Metabolic results were confirmed in primary human hepatocytes. Results: We demonstrate that the grapefruit flavonoid naringenin dose-dependently inhibits HCV production without affecting intracellular levels of the viral RNA or protein. We show that naringenin blocks the assembly of intracellular infectious viral particles, upstream of viral egress. This antiviral effect is mediated in part by the activation of PPARa, leading to a decrease in VLDL production without causing hepatic lipid accumulation in Huh7.5.1 cells and primary human hepatocytes. Long-term treatment with naringenin leads to a rapid 1.4 log reduction in HCV, similar to 1000 U of interferon. During the washout period, HCV levels returned to normal, consistent with our proposed mechanism of action. Conclusions: The data demonstrates that naringenin is a nontoxic assembly inhibitor of HCV and that other PPARa agonists play a similar role in blocking viral production. The combination of naringenin with STAT-C agents could potentially bring a rapid reduction in HCV levels during the early treatment phase, an outcome associated with sustained virological response. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:963 / 971
页数:9
相关论文
共 43 条
[1]
Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes [J].
Allister, EM ;
Borradaile, NM ;
Edwards, JY ;
Huff, MW .
DIABETES, 2005, 54 (06) :1676-1683
[2]
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles [J].
André, P ;
Komurian-Pradel, F ;
Deforges, S ;
Perret, M ;
Berland, JL ;
Sodoyer, M ;
Pol, S ;
Bréchot, C ;
Paranhos-Baccalà, G ;
Lotteau, V .
JOURNAL OF VIROLOGY, 2002, 76 (14) :6919-6928
[3]
Bhan AK, 2007, CANCER
[4]
Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor α and carnitine palmitoyl acyl-CoA transferase 1A [J].
Cheng, Yang ;
Dharancy, Sebastien ;
Malapel, Mathilde ;
Desreumaux, Pierre .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (48) :7591-7596
[5]
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia [J].
Cuchel, Marina ;
Bloedon, LeAnne T. ;
Szapary, Philippe O. ;
Kolansky, Daniel M. ;
Wolfe, Megan L. ;
Sarkis, Antoine ;
Millar, John S. ;
Ikewaki, Katsunori ;
Siegelman, Evan S. ;
Gregg, Richard E. ;
Rader, Daniel J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :148-156
[6]
Statins Potentiate the In Vitro Anti-Hepatitis C Virus Activity of Selective Hepatitis C Virus Inhibitors and Delay or Prevent Resistance Development [J].
Delang, Leen ;
Paeshuyse, Jan ;
Vliegen, Inge ;
Leyssen, Pieter ;
Obeid, Susan ;
Durantel, David ;
Zoulim, Fabien ;
de Beeck, Anne Op ;
Neyts, Johan .
HEPATOLOGY, 2009, 50 (01) :6-16
[7]
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection [J].
Dharancy, S ;
Malapel, M ;
Perlemuter, G ;
Roskams, T ;
Cheng, Y ;
Dubuquoy, L ;
Podevin, P ;
Conti, F ;
Canva, V ;
Philippe, D ;
Gambiez, L ;
Mathurin, P ;
Paris, JC ;
Schoonjans, K ;
Calmus, Y ;
Pol, S ;
Auwerx, J ;
Desreumaux, P .
GASTROENTEROLOGY, 2005, 128 (02) :334-342
[8]
Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics [J].
Diamond, Deborah L. ;
Syder, Andrew J. ;
Jacobs, Jon M. ;
Sorensen, Christina M. ;
Walters, Kathie-Anne ;
Proll, Sean C. ;
McDermott, Jason E. ;
Gritsenko, Marina A. ;
Zhang, Qibin ;
Zhao, Rui ;
Metz, Thomas O. ;
Camp, David G., II ;
Waters, Katrina M. ;
Smith, Richard D. ;
Rice, Charles M. ;
Katze, Michael G. .
PLOS PATHOGENS, 2010, 6 (01)
[9]
Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin [J].
Fujita, N. ;
Kaito, M. ;
Kai, M. ;
Sugimoto, R. ;
Tanaka, H. ;
Horiike, S. ;
Konishi, M. ;
Iwasa, M. ;
Watanabe, S. ;
Adachi, Y. .
JOURNAL OF VIRAL HEPATITIS, 2006, 13 (07) :441-448
[10]
FUJIWARA T, 1988, J BIOL CHEM, V263, P18545